Gefitinib

CAS: 184475-35-2

Ref. TM-T1181

Produktinformation

• Name: Gefitinib
• Synonyme: ZD1839, (3-Chloro-4-fluorophenyl)[7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-yl]amine, 4-(3-Chloro-4-fluorophenylamino)-7-methoxy-6-[3-(4-morpholinyl)propoxy]quinazoline, 4-(3′-Chloro-4′-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline, 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]-, Akos 91371, Gefitinib Base, Gefitinib(TINIBS), Gefitinib, Iressa, ZD1839, Gefonib, Geftinib, N-(3-Chloro-4-Fluoro-Phenyl)-7-Methoxy-6-(3-Morpholin-4-Ylpropoxy)Quinazolin-4-Amine, N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine, N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]-4-quinazolinamine, Zd 1839, Zd1839
• CAS: 184475-35-2

Beschreibung

Gefitinib (ZD1839) is an EGFR first-generation inhibitor with oral activity that inhibits the EGFR 19 Del and L858R mutations. Gefitinib has antitumor activity and is used for the treatment of EGFR-mutated non-small-cell lung cancers. Gefitinib administration RESULTS in the development of the EGFR C797S resistance mutation.

• Marke: Targetmol

Chemische Eigenschaften

• Molekulargewicht: 446.9
• Formel: C₂₂H₂₄ClFN₄O₃
• Reinheit: 100%
• Farbe/Form: Light-Yellow Crystalline Powder